Market Overview:
The global atrial fibrillation drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of atrial fibrillation, rising geriatric population, and technological advancements in the field of medical devices. The global atrial fibrillation drugs market is segmented on the basis of type into anti-arrhythmic drugs and anti-coagulant drugs. The anti-arrhythmic drug segment is further divided into class I agents, class II agents, class III agents, and other anti-arrhythmic drugs. The class I agent segment is expected to dominate the global atrial fibrillation drug market during the forecast period owing to its high usage rates for treating various types of arrhythmias. The anti-coagulant drug segment includes warfarin sodium (Coumadin), rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran etexilate mesylate (Pradaxa), edoxaban (Savaysa) and others.
Product Definition:
Atrial Fibrillation Drugs are drugs that are used to treat atrial fibrillation. Atrial fibrillation is a type of arrhythmia, or abnormal heart rhythm, in which the heart's two upper chambers (the atria) beat chaotically and irregularly. This can lead to blood pooling in the atria, which can increase the risk of blood clots forming and traveling to the brain, where they can cause a stroke. Atrial fibrillation drugs help to restore a regular heart rhythm and reduce the risk of blood clots forming.
Anti-Arrhythmic Drugs:
Anti-arrhythmic drugs are used to treat cardiac arrhythmias. These are the most commonly reported causes of death in developed countries. According to the CDC, heart disease is responsible for around 735,000 deaths per year and stroke another nongovernment organization estimates around 160,000 deaths per year globally.
The global anti-arrhythmic drugs market was valued at over USD 12 billion in 2015.
Anti-Coagulant Drugs:
Anti-coagulant drugs are used to prevent blood clotting. They work by decreasing or interrupting the action of a certain chemical in the body, which prevents blood from coagulating (coming together) when it is near injuries and wounds. Anti-coagulants are also used to treat bleeding diathesis (caused by) conditions such as cancer and gastrointestinal diseases among others.
Application Insights:
Paroxysmal atrial fibrillation held the largest share of 24.1% in 2017 owing to its high prevalence and treatment rates. It is also the most common type of AF, affecting around 1 in every 5 individuals across the globe. The condition occurs more frequently in males than females and usually affects people above 50 years of age.
The long-term prognosis for patients suffering from paroxysmal atrial fibrillation is good when compared with those suffering from chronic AF; however, these patients face higher healthcare costs due to a longer hospital stay as well as drug prescription during initial stages of treatment. According to data published by CDC, around 60%of people with paroxysmal atrial fibrillation are receiving recommended treatments worldwide while 30% are not getting any follow-up care despite having stable disease for over 2 years since their last contact with a healthcare professional (i.e., outpatient).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to favorable government initiatives, increasing prevalence of AF and other associated diseases, technological advancements, and high healthcare expenditure in this region. Moreover, the presence of key pharmaceutical companies that are engaged in developing novel drugs for treatment of AF is expected to boost the growth further.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising geriatric population base with atrial fibrillation (AF) who require long-term therapy as well as a higher incidence rate of paroxysmal forms among them. In addition, improving healthcare infrastructure along with growing awareness about early diagnosis & treatment will drive regional market during the forecast period. Furthermore, availability of generic drugs due to patent expirations or regulatory changes may also contribute toward revenue generation during future years (i).
Growth Factors:
- Increasing prevalence of atrial fibrillation
- Growing geriatric population
- Rising awareness about the benefits of atrial fibrillation drugs
- Technological advancements in atrial fibrillation drugs market
- Increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Atrial Fibrillation Drugs Market Research Report
By Type
Anti-Arrhythmic Drugs, Anti-Coagulant Drugs
By Application
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
By Companies
Boehringer Ingelheim, Janssen Pharmaceuticals, Sanofi, ARCA Biopharma, Armetheon, Baxter, Bristol-Myers Squibb, ChanRx, Daiichi Sankyo, Gilead Sciences, Boehringer Ingelheim, Menarini, Pfizer, Pierre Fabre, Servier, Xention
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Atrial Fibrillation Drugs Market Report Segments:
The global Atrial Fibrillation Drugs market is segmented on the basis of:
Types
Anti-Arrhythmic Drugs, Anti-Coagulant Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- Sanofi
- ARCA Biopharma
- Armetheon
- Baxter
- Bristol-Myers Squibb
- ChanRx
- Daiichi Sankyo
- Gilead Sciences
- Boehringer Ingelheim
- Menarini
- Pfizer
- Pierre Fabre
- Servier
- Xention
Highlights of The Atrial Fibrillation Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-Arrhythmic Drugs
- Anti-Coagulant Drugs
- By Application:
- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation
- Longstanding Persistent Atrial Fibrillation
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Atrial Fibrillation Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Atrial Fibrillation Drugs are medications that help to lower the risk of stroke in people with atrial fibrillation.
Some of the key players operating in the atrial fibrillation drugs market are Boehringer Ingelheim, Janssen Pharmaceuticals, Sanofi, ARCA Biopharma, Armetheon, Baxter, Bristol-Myers Squibb, ChanRx, Daiichi Sankyo, Gilead Sciences, Boehringer Ingelheim, Menarini, Pfizer, Pierre Fabre, Servier, Xention.
The atrial fibrillation drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Atrial Fibrillation Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Atrial Fibrillation Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Atrial Fibrillation Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Atrial Fibrillation Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Atrial Fibrillation Drugs Market Size & Forecast, 2018-2028 4.5.1 Atrial Fibrillation Drugs Market Size and Y-o-Y Growth 4.5.2 Atrial Fibrillation Drugs Market Absolute $ Opportunity
Chapter 5 Global Atrial Fibrillation Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Atrial Fibrillation Drugs Market Size Forecast by Type
5.2.1 Anti-Arrhythmic Drugs
5.2.2 Anti-Coagulant Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Atrial Fibrillation Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Atrial Fibrillation Drugs Market Size Forecast by Applications
6.2.1 Paroxysmal Atrial Fibrillation
6.2.2 Persistent Atrial Fibrillation
6.2.3 Longstanding Persistent Atrial Fibrillation
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Atrial Fibrillation Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Atrial Fibrillation Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Atrial Fibrillation Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Atrial Fibrillation Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Atrial Fibrillation Drugs Market Size Forecast by Type
9.6.1 Anti-Arrhythmic Drugs
9.6.2 Anti-Coagulant Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Atrial Fibrillation Drugs Market Size Forecast by Applications
9.10.1 Paroxysmal Atrial Fibrillation
9.10.2 Persistent Atrial Fibrillation
9.10.3 Longstanding Persistent Atrial Fibrillation
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Atrial Fibrillation Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Atrial Fibrillation Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Atrial Fibrillation Drugs Market Size Forecast by Type
10.6.1 Anti-Arrhythmic Drugs
10.6.2 Anti-Coagulant Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Atrial Fibrillation Drugs Market Size Forecast by Applications
10.10.1 Paroxysmal Atrial Fibrillation
10.10.2 Persistent Atrial Fibrillation
10.10.3 Longstanding Persistent Atrial Fibrillation
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Atrial Fibrillation Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Atrial Fibrillation Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Atrial Fibrillation Drugs Market Size Forecast by Type
11.6.1 Anti-Arrhythmic Drugs
11.6.2 Anti-Coagulant Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Atrial Fibrillation Drugs Market Size Forecast by Applications
11.10.1 Paroxysmal Atrial Fibrillation
11.10.2 Persistent Atrial Fibrillation
11.10.3 Longstanding Persistent Atrial Fibrillation
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Atrial Fibrillation Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Atrial Fibrillation Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Atrial Fibrillation Drugs Market Size Forecast by Type
12.6.1 Anti-Arrhythmic Drugs
12.6.2 Anti-Coagulant Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Atrial Fibrillation Drugs Market Size Forecast by Applications
12.10.1 Paroxysmal Atrial Fibrillation
12.10.2 Persistent Atrial Fibrillation
12.10.3 Longstanding Persistent Atrial Fibrillation
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Atrial Fibrillation Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Atrial Fibrillation Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Atrial Fibrillation Drugs Market Size Forecast by Type
13.6.1 Anti-Arrhythmic Drugs
13.6.2 Anti-Coagulant Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Atrial Fibrillation Drugs Market Size Forecast by Applications
13.10.1 Paroxysmal Atrial Fibrillation
13.10.2 Persistent Atrial Fibrillation
13.10.3 Longstanding Persistent Atrial Fibrillation
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Atrial Fibrillation Drugs Market: Competitive Dashboard
14.2 Global Atrial Fibrillation Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Boehringer Ingelheim
14.3.2 Janssen Pharmaceuticals
14.3.3 Sanofi
14.3.4 ARCA Biopharma
14.3.5 Armetheon
14.3.6 Baxter
14.3.7 Bristol-Myers Squibb
14.3.8 ChanRx
14.3.9 Daiichi Sankyo
14.3.10 Gilead Sciences
14.3.11 Boehringer Ingelheim
14.3.12 Menarini
14.3.13 Pfizer
14.3.14 Pierre Fabre
14.3.15 Servier
14.3.16 Xention